- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03941015
Tissue Oxygenation During Treatment of Infant Congenital Heart Defects
Background: Acute kidney injury (AKI) is a common and serious postoperative complication in children with congenital heart disease. In this prospective cohort study, we tested the hypothesis that renal desaturation defined as a 20% decline of renal tissue oxygen saturation (SrtO2) from the baseline value is associated with AKI in infants undergoing ventricular septal defect (VSD) repair with cardiopulmonary bypass (CPB).
Methods: Infants aged 1 months to 12 months and scheduled to undergo VSD repair with CPB were eligible. SrtO2 was monitored using a tissue near-infrared spectroscopy. Renal desaturation was defined as a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s. The primary outcome was the incidence of AKI on postoperative 1-3 days according to the Kidney Disease: Improving Global Outcomes criteria. The secondary outcomes included different stages of AKI, duration of postoperative mechanical ventilation, duration of intensive care unit (ICU) and hospital stay, renal replacement therapy (RRT), and in-hospital mortality.
Study Overview
Status
Detailed Description
Using near-infrared spectroscopy (NIRS) to monitor intraoperative and postoperative tissue oxygen saturation and to investigate the correlation with postoperative complications.
Intraoperative hemodynamic parameters were monitored by Mostcare(PRAM, Vygon Health, Padua, Italy) including cardiac index, systemic vascular resistance index, stroke volume index, the maximal slope of systolic upstroke, cardiac cycle efficiency.
SrtO2 was monitored using a tissue near-infrared spectroscopy (FORE-SIGHT ELITE tissue oximeter, CASMED, Branford, Connecticut, USA; now acquired by Edwards Lifesciences, Irvine, California, USA). A biophotonic sensor was placed on the left flank at the level of T10-L2 to monitor SrtO2. The tissue oximeter generated a new SrtO2 data every 2 seconds. All these data were exported from the monitor as the end of surgery. As this is an observational study, the SrtO2 data were only used for research purpose, not for clinical decision making. The function of tissue oximeter was checked by a dedicated research personnel in the operating room. The infant was dropped from the study if the SrtO2 measurements were not available for more than 5 min during surgery. The baseline SrtO2 was defined as the median value of the 5-minute measurements which were measured following anesthesia induction and during the period when the cardiac index ≥2.5 L/min/m2. Renal desaturation was defined as a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
The electronic data streams from the NIRS and other patient monitors will be collected into a study computer. Data collection will initiate at pre-induction of anesthesia in the operating room. Only the NIRS values will be blinded from clinical use. Blood samples for determining biomarkers of ischemic tissue injury will be taken at defined intervals. No other modifications to clinical practice will occur while conducting the study and the NIRS monitoring is non-invasive.
The primary outcome was the incidence of AKI within 3 days after surgery according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary outcomes including different stages of AKI, duration of postoperative mechanical ventilation, duration of intensive care unit (ICU) and hospital stay, and in-hospital mortality.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Anzhen hospital, Beijing
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≤ 1 year
- Diagnosis of ventricular septal defect
- Undergoing cardiac surgery with cardiopulmonary bypass
Exclusion Criteria:
- refusal to participate;
- emergent or urgent surgery;
- weight >10 kg;
- preoperative renal dysfunction;
- multiple organ dysfunction;
- chromosomal abnormalities;
- skin condition precluding the application of near-infrared spectroscopy probe.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
patients with renal desaturation
Patients who underwent a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
|
patients without renal desaturation
Patients who didn't undergo a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Acute Kidney Injury
Time Frame: 3 days
|
AKI was diagnosed per the Kidney Disease: Improving Global Outcomes (KDIGO) criteria.
Acute kidney injury was defined as an increase in serum creatinine to ≥1.5 times baseline within 3 days after surgery.
Serum creatinine was recorded within one week before surgery and on postoperative days 1-3.
Serum creatinine measured within one week before surgery was defined as serum creatinine baseline.
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Mechanical Ventilation
Time Frame: up to 1440 hours
|
Hours of mechanical ventilation after surgery
|
up to 1440 hours
|
Length of Hospital Stay
Time Frame: up to 60 days
|
Length of hospital stay after surgery
|
up to 60 days
|
Duration of Stay in the Intensive Care Unit
Time Frame: up to 60 days
|
Duration of Stay in the intensive care unit after surgery
|
up to 60 days
|
Number of Participants Reaching Kidney Disease: Improving Global Outcomes (KDIGO) Stage 1
Time Frame: 3 days
|
KDIGO stage 1 was defined as serum creatinine increased more than 1.5 times serum creatinine baseline.
Serum creatinine was recorded within one week before surgery and on postoperative days 1-3.
Serum creatinine measured one week before surgery was defined as serum creatinine baseline.
KDIGO stage 1 was considered as mild acute kidney injury.
|
3 days
|
Number of Participants Reaching Kidney Disease: Improving Global Outcomes (KDIGO) Stage 2
Time Frame: 3 days
|
KDIGO stage 2 was defined as serum creatinine increased more than 2 times serum creatinine baseline and less than 3 times serum creatinine baseline.
Serum creatinine was recorded within one week before surgery and on postoperative days 1-3.
Serum creatinine measured one week before surgery was defined as serum creatinine baseline.
Acute kidney injury in KDIGO stage 2 was more serious than acute kidney injury in stage 1.
|
3 days
|
Number of Participants Reaching Kidney Disease: Improving Global Outcomes (KDIGO) Stage 3
Time Frame: 3 days
|
KDIGO stage 3 was defined as serum creatinine increased more than 3 times baseline, or dialysis requirement, or estimated GFR less than 35 mL/min/1.73m2.
Serum creatinine was recorded within one week before surgery and on postoperative days 1-3.
Serum creatinine measured one week before surgery was defined as serum creatinine baseline.
Acute kidney injury in KDIGO stage 3 was more serious than acute kidney injury in stage 2.
|
3 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Boqun Cui, MA, Anzhen hospital Beijing China
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Kidney Diseases
- Urologic Diseases
- Peritoneal Diseases
- Congenital Abnormalities
- Gastrointestinal Diseases
- Renal Insufficiency
- Intestinal Diseases
- Signs and Symptoms, Respiratory
- Cardiovascular Abnormalities
- Hypoxia, Brain
- Brain Ischemia
- Ischemia
- Acute Kidney Injury
- Heart Defects, Congenital
- Hypoxia
- Hypoxia-Ischemia, Brain
- Mesenteric Ischemia
Other Study ID Numbers
- 2018009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
-
Xuzhou Medical UniversityUnknownPostoperative Acute Kidney Injury